PIPELINE
Oncolytic Vaccines
for Cancer Immunotherapy
Cancers grow and spread because tumor cells have developed ways to evade detection and destruction by the immune system. Cancer immunotherapies—also known as immuno-oncology drugs—encompass a range of promising new drug treatment approaches that harness the immune system to kill tumor cells while also providing long-term tumor destruction.

In partnership with biotechnology and pharmaceutical companies, Profectus is pursuing the development of oncolytic vaccines that selectively destroy tumors while simultaneously boosting patients’ immune systems to continue killing any residual cancer cells that may survive the initial virus attack.

Types of Cancer Vaccines

Profectus oncolytic vaccines are based on rVSV-derived vaccine vectors that we engineer to prime the immune system to generate a robust and durable cellular immune response. The goal is to promote more sustained cancer cell-destroying activity, increasing drug effectiveness with enhanced safety and immunogenicity.
Profectus’ recombinant vesicular stomatitus virus (rVSV)-derived VesiculoVax™ vaccine vectors are engineered to prime the immune system to generate a robust and durable cellular immune response to promote more sustained cancer cell-destroying activity, increasing drug effectiveness with enhanced safety and immunogenicity.

Our vectors may be paired with other anticancer treatment strategies—including immunotherapy modalities such as oncolytic viruses and checkpoint inhibitors, or other forms of therapy such as chemotherapy and newer targeted therapies—to enhance the efficacy of immunotherapy and improve cancer treatment outcomes.


Profectus and Vyriad have entered into a global collaboration agreement to develop oncolytic vesiculovirus vaccines for the treatment of advanced-stage cancers. The companies are combining and leveraging their respective recombinant vesicular stomatitus virus (rVSV)-derived oncolytic and vaccine platform technologies to develop novel cancer drugs that selectively destroy tumors while simultaneously boosting patients’ immune systems to continue killing any residual cancer cells that may survive the initial virus attack. This partnership consolidates the foundational technology established for the use of rVSVs in vaccine development developed by the John K. Rose laboratory at Yale University.

Profectus-Vyriad Oncolytic Vaccine Immunotherapies: Dual Mechanism of Tumor Destruction

Profectus-Vyriad oncolytic vaccines are derived from vesiculoviruses— naturally occurring viruses engineered to selectively infect and destroy cancer/tumor cells and generate a tumor-specific immune response, without harming healthy cells. The oncolytic vaccines incorporate technologies from both companies, including:
  • Profectus vaccine vectors derived from vesiculoviruses that are engineered to generate a robust and durable anti-tumor immune response, resulting in sustained cancer cell-destroying activity
  • Vyriad oncolytic viruses derived from vesiculoviruses and engineered to infect, selectively replicate in, and destroy tumors/cancer cells with enhanced specificity, potency, and safety
© 2017 Profectus BioSciences, Inc. All Rights Reserved.  |  User Login